We are monitoring the impact of COVID-19 on North America Leukemia Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 765
Share on
Share on

North America Leukemia Therapeutics Market Research Report - Segmented By Disease Condition, Diagnosis, Treatments, Drugs & Country (United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 765
Pages: 145

North America Leukemia Therapeutics Market Size (2021 to 2026)

The size of the North America Leukemia Therapeutics market is estimated to worth USD 3.70 billion by 2026 and USD 2.42 billion in 2021, growing at a CAGR of 8.9% during the forecast period.

The growing incidence of leukemia patients, high unmet medical demand for cancer therapy, and increased investment in healthcare sectors drive the North America Leukemia therapeutics market. Over the forecast period, the market is anticipated to be driven by the launch of new treatments with greater efficacy and fewer adverse effects, metabolic inhibitors, as well as innovation in drug development, increased number of biotechnology businesses, increased expenditures in the R&D sector, and pipeline drugs awaiting approval. For chemo-resistant B cell acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), new immune-based treatments such as CAR T cells, immune checkpoint blockers (ICBs), and bi-specific T cell engagers (BITES) are being explored as viable therapy alternatives. In addition, in this industry, bone marrow transplantation and stem cell treatments are emerging trends projected to boost growth in this region.

The introduction of new therapeutics and favorable government initiatives are expected to create potential growth opportunities for the leading players in the North American leukemia therapeutics market. In the next few years, the growing number of instances of leukemia and the expansion of healthcare infrastructure is expected to drive the overall market's growth. In addition, multiple treatment landscapes and a family history of leukemia treatments are thought to be favorable indicators for novel drug demand. To preserve their competitive advantage, several companies are concentrating on service providing medicines for leukemia treatment. Chemotherapy is, therefore, the most common treatment choice for most people with leukemia. Furthermore, an increase in financing for businesses active in leukemia research is likely to promote market growth. The elements predicted to contribute to the expansion of this industry include increasing patient awareness of the newest technological advancements in treatments and benefits such as tolerability, efficacy, and safety.

The high cost of developing new medicines is expected to hinder the North American leukemia therapeutics market expansion. Furthermore, alternative treatment methods, such as radiation, have specific side effects that may limit leukemia therapeutic products. As a result, the market's expansion is limited by side effects and unfavorable responses connected with the products. Chemotherapy, for example, causes hair loss, infections, skin issues, high blood pressure, fatigue, and other negative side effects.

This research report on the North America Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories.

By Disease Condition:              

  • Chronic Lymphatic Leukemia           
  • Acute Lymphatic Leukemia              
  • Chronic Myeloid Leukemia               
  • Acute Myeloid Leukemia  

By Diagnosis:

  • CT scan     
  • Biopsy       
  • MRI            

By Treatments:

  • Chemotherapy      
  • Radiation therapy
  • Immunotherapy   
  • Surgery     
  • Targeted Therapy
  • Bone marrow transplant   
  • Stem Cell Therapy

By Drugs:

  • Gleevec    
  • Sapacitabine           
  • GA101       
  • Vasaroxine              
  • Tosedosat      

By Country:

  • United States
  • Canada
  • Rest of North America

Geographically, North America holds the largest share in the global market, followed by Europe. However, several factors such as the rising prevalence of leukemia and increasing penetration of companies into the market with increasing R&D involvement create opportunities for market growth in the Leukemia Therapeutics market in the North American region.

The market for leukemia treatments in North America is expected to develop rapidly throughout the forecast period. This region's strong rise can be attributed to consumers' growing awareness of the availability of effective treatments in the coming years. North America was the largest regional market, owing to rising patient awareness, technological advancements, supporting government policies in terms of incentives and investments, and advanced healthcare infrastructure, among other factors. In addition, this market has grown as a consequence of increased research in regenerative medicine for the treatment of leukemia and increased awareness of customized medicine. Furthermore, the high frequency and incidence of leukemia and the growing elderly population are driving this market's expansion.

KEY MARKET PLAYERS:

A few of the key companies operating in the North America Leukemia Therapeutics market profiled in this report are Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Disease Condition                              

                                5.1.1 Chronic Lymphatic Leukemia           

                                5.1.2 Acute Lymphatic Leukemia              

                                5.1.3 Chronic Myeloid Leukemia               

                                5.1.4 Acute Myeloid Leukemia  

                5.2 By Diagnosis                               

                                5.2.1 CT scan     

                                5.2.2 Biopsy       

                                5.2.3 MRI            

                5.3 By Treatments                          

                                5.3.1 Chemotherapy      

                                5.3.2 Radiation therapy

                                5.3.3 Immunotherapy   

                                5.3.4 Surgery     

                                5.3.5 Targeted Therapy

                                5.3.6 Bone marrow transplant   

                                5.3.7 Stem Cell Therapy

                5.4 By Drugs                      

                                5.4.1 Gleevec    

                                5.4.2 Sapacitabine           

                                5.4.3 GA101       

                                5.4.4 Vasaroxine              

                                5.4.5 Tosedosat               

6. Geographical Analysis                                              

                                6.1 Introduction               

                                6.2 United States            

                                6.3 Canada         

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials                               

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target     

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target   

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.            

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 F. Hoffmann-La Roche Ltd                    

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 GlaxoSmithKline Pharmaceuticals Limited                     

                9.3 Novartis International AG                    

                9.4 Bristol-Myers Squibb                              

                9.5 Eisai Co. Ltd                

                9.6 Biogen Idec                                

                9.7 ERYtech Pharma                       

                9.8 Celgene Corporation                              

                9.9 Genmab A/S                              

                9.10 Cephalon Inc.                          

                9.11 Clavis Pharma                          

                9.12 Pfizer Inc.                  

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                      

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

 

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Leukemia Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. North America Leukemia Therapeutics Market, By Disease condition, From 2021 to 2026 (USD Billion)
  3. North America Cchronic Lymphatic Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Acute Lymphatic Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  5. North America Chronic Myeloid Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Acute Myeloid Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Leukemia Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  8. North America Leukemia CT scan Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Leukemia Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Leukemia MRI Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Leukemia Therapeutics Market, By Treatments, From 2021 to 2026 (USD Billion)
  12. North America Leukemia Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Leukemia Radiation Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America Leukemia Immunotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  15. North America Leukemia Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  16. North America Leukemia Targeted Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  17. North America Leukemia Bone marrow transplant Market, By Region, From 2021 to 2026 (USD Billion)
  18. North America Leukemia Stem Cell Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  19. North America Leukemia Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  20. North America Leukemia Gleevec Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Leukemia Sepecitabine Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America Leukemia GA101 Market, By Region, From 2021 to 2026 (USD Billion)
  23. North America Leukemia Vasaroxine Market, By Region, From 2021 to 2026 (USD Billion)
  24. North America Leukemia Tosedosat Market, By Region, From 2021 to 2026 (USD Billion)
  25. United States Leukemia Therapeutics Market, By Disease condition, From 2021 to 2026 (USD Billion)
  26. United States Leukemia Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  27. United States Leukemia Therapeutics Market, By Treatments, From 2021 to 2026 (USD Billion)
  28. United States Leukemia Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  29. Canada Leukemia Therapeutics Market, By Disease condition, From 2021 to 2026 (USD Billion)
  30. Canada Leukemia Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  31. Canada Leukemia Therapeutics Market, By Treatments, From 2021 to 2026 (USD Billion)
  32. Canada Leukemia Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample